Advertisement
YOU ARE HERE: LAT HomeCollectionsThousand Oaks Based Amgen
IN THE NEWS

Thousand Oaks Based Amgen

FEATURED ARTICLES
BUSINESS
November 8, 2008 | Times Wire Services
Amgen Inc. said it hoped to begin selling its bone drug denosumab next year, fueling growth as the decline in revenue from its top-selling anemia treatments bottoms out. The company plans to file by the end of this year or early 2009 for U.S. approval of denosumab, Thousand Oaks-based Amgen has said.
ARTICLES BY DATE
BUSINESS
January 26, 2012 | By Tiffany Hsu
Biotech giant Amgen is hoping to bolster its cancer drug pipeline by buying fellow drug developer Micromet Inc. for $1.16 billion. At $11 a share, with an Amgen subsidiary buying the majority of Micromet's stock and then the Amgen parent company picking up the rest, the price represents a 33% premium on Micromet's closing price Wednesday. Thousand Oaks-based Amgen is itself among the world's premier drug makers but hasn't had many popular drugs in years. Rockville, Md.-based Micromet, meanwhile, is testing a promising treatment for leukemia and non-Hodgkin's lymphoma.
Advertisement
BUSINESS
March 13, 2008 | From Times Wire Services
A U.S. advisory panel unanimously urged regulators to approve an Amgen Inc. drug for a rare blood disorder that puts patients at risk of bleeding. The Food and Drug Administration advisors said the benefits of Nplate outweighed the risks for treating chronic immune thrombocytopenia purpura. The FDA usually follows the panel's recommendations. Thousand Oaks-based Amgen said it expected a final ruling in the first half of this year.
BUSINESS
March 30, 2011 | Bloomberg News
An experimental treatment for lung cancer made by Amgen Inc. and Takeda Pharmaceutical Co. failed to help patients live longer in a late-stage study. The medication, motesanib, didn't meet its main goal of improving survival in a study of 1,090 patients with non-squamous non-small cell lung cancer, the companies said Wednesday. Amgen and Osaka, Japan-based Takeda haven't decided whether to continue developing the drug, said Christine Regan, an Amgen spokeswoman. Motesanib was one of three cancer drugs in late-stage testing for Thousand Oaks-based Amgen, the world's largest biotechnology company.
BUSINESS
October 11, 2008 | From Times Wire Services
Roche Holding was barred by an appeals court from selling the anemia drug Mircera in the U.S. after a judge found that the Swiss company infringed patents held by Thousand Oaks-based Amgen Inc. The U.S. Court of Appeals for the Federal Circuit upheld a February order by U.S. District Judge William Young in Boston without comment. Young ruled last week that U.S. sales of Mircera should be blocked until the patents expire.
BUSINESS
November 21, 2008 | Times Wire Services
Amgen Inc.'s decision to suspend a clinical trial of its experimental cancer drug motesanib because of higher deaths among patients sets back the company's efforts to expand in the market for oncology treatments. Thousand Oaks-based Amgen and Japan's Takeda Pharmaceutical Co. were testing the drug as a first-line treatment in combination with chemotherapy for non-small cell lung cancer, the companies said this week. The trial was halted after an independent monitoring committee's review of 600 patients found higher early mortality rates among those getting the drug compared with those on a placebo.
BUSINESS
August 23, 2008 | From the Associated Press
Federal regulators Friday approved a biotech drug from Amgen Inc. to treat a rare blood clotting disorder. The Food and Drug Administration approved Nplate for patients with a disorder that causes the body to attack its own platelets, which are tiny components of blood that help with clotting. The condition called thrombocytopenia can cause bruising and bleeding after minor injuries. According to Thousand Oaks-based Amgen, it affects an estimated 60,000 adult patients in the U.S. Nplate is the first drug that directly encourages platelet production by stimulating the patient's bone marrow, regulators said.
BUSINESS
January 26, 2012 | By Tiffany Hsu
Biotech giant Amgen is hoping to bolster its cancer drug pipeline by buying fellow drug developer Micromet Inc. for $1.16 billion. At $11 a share, with an Amgen subsidiary buying the majority of Micromet's stock and then the Amgen parent company picking up the rest, the price represents a 33% premium on Micromet's closing price Wednesday. Thousand Oaks-based Amgen is itself among the world's premier drug makers but hasn't had many popular drugs in years. Rockville, Md.-based Micromet, meanwhile, is testing a promising treatment for leukemia and non-Hodgkin's lymphoma.
BUSINESS
March 30, 2011 | Bloomberg News
An experimental treatment for lung cancer made by Amgen Inc. and Takeda Pharmaceutical Co. failed to help patients live longer in a late-stage study. The medication, motesanib, didn't meet its main goal of improving survival in a study of 1,090 patients with non-squamous non-small cell lung cancer, the companies said Wednesday. Amgen and Osaka, Japan-based Takeda haven't decided whether to continue developing the drug, said Christine Regan, an Amgen spokeswoman. Motesanib was one of three cancer drugs in late-stage testing for Thousand Oaks-based Amgen, the world's largest biotechnology company.
BUSINESS
August 13, 1991 | JAMES F. PELTZ, TIMES STAFF WRITER
On Sept. 10, stockholders of Amgen Inc. will receive two additional shares of the biotechnology concern for every share they now own. In other words, Amgen is having a 3-for-1 stock split. Amgen, based in Thousand Oaks, also announced plans to change the end of its fiscal year to Dec. 31 from March 31. Both moves, which dozens of other companies also make each year, appear to be little more than paper-shuffling exercises.
BUSINESS
November 21, 2008 | Times Wire Services
Amgen Inc.'s decision to suspend a clinical trial of its experimental cancer drug motesanib because of higher deaths among patients sets back the company's efforts to expand in the market for oncology treatments. Thousand Oaks-based Amgen and Japan's Takeda Pharmaceutical Co. were testing the drug as a first-line treatment in combination with chemotherapy for non-small cell lung cancer, the companies said this week. The trial was halted after an independent monitoring committee's review of 600 patients found higher early mortality rates among those getting the drug compared with those on a placebo.
BUSINESS
November 8, 2008 | Times Wire Services
Amgen Inc. said it hoped to begin selling its bone drug denosumab next year, fueling growth as the decline in revenue from its top-selling anemia treatments bottoms out. The company plans to file by the end of this year or early 2009 for U.S. approval of denosumab, Thousand Oaks-based Amgen has said.
BUSINESS
October 11, 2008 | From Times Wire Services
Roche Holding was barred by an appeals court from selling the anemia drug Mircera in the U.S. after a judge found that the Swiss company infringed patents held by Thousand Oaks-based Amgen Inc. The U.S. Court of Appeals for the Federal Circuit upheld a February order by U.S. District Judge William Young in Boston without comment. Young ruled last week that U.S. sales of Mircera should be blocked until the patents expire.
BUSINESS
August 23, 2008 | From the Associated Press
Federal regulators Friday approved a biotech drug from Amgen Inc. to treat a rare blood clotting disorder. The Food and Drug Administration approved Nplate for patients with a disorder that causes the body to attack its own platelets, which are tiny components of blood that help with clotting. The condition called thrombocytopenia can cause bruising and bleeding after minor injuries. According to Thousand Oaks-based Amgen, it affects an estimated 60,000 adult patients in the U.S. Nplate is the first drug that directly encourages platelet production by stimulating the patient's bone marrow, regulators said.
BUSINESS
March 13, 2008 | From Times Wire Services
A U.S. advisory panel unanimously urged regulators to approve an Amgen Inc. drug for a rare blood disorder that puts patients at risk of bleeding. The Food and Drug Administration advisors said the benefits of Nplate outweighed the risks for treating chronic immune thrombocytopenia purpura. The FDA usually follows the panel's recommendations. Thousand Oaks-based Amgen said it expected a final ruling in the first half of this year.
BUSINESS
August 20, 1991 | JAMES F. PELTZ, TIMES STAFF WRITER
On Sept. 10, stockholders of Amgen Inc. will receive two additional shares of the biotechnology concern for every share they now own. In other words, Amgen is having a 3-for-1 stock split. Amgen, based in Thousand Oaks, also announced plans to change the end of its fiscal year to Dec. 31 from March 31. Both moves, which dozens of other companies also make each year, appear to be little more than paper-shuffling exercises.
Los Angeles Times Articles
|